GALNT9 and prostate adenocarcinoma: Based on Beltran human PCa dataset,[18] volcano plots revealed that the glycosyltransferase GALNT9 (encoded by GALNT9), which catalyzes O‐GalNAc glycosylation by adding the glycan of GalNAc to substrates, was most significantly upregulated in patients with NEPC compared with patients with PrAD (Figure4a).